Morgan Stanley
ADIL

Morgan Stanley’s Adial Pharmaceuticals ADIL Stock Holding History

Morgan Stanley’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$90 Buy
+50
New +$176 ﹤0.01% 7816
2025
Q4 		– Hold
0
– – – 8171
2025
Q3 		– Hold
0
– – – 8137
2025
Q2 		– Hold
0
– – – 8060
2025
Q1 		– Hold
0
– – – 8022
2024
Q4 		– Sell
-12
Closed -$312 – 7912
2024
Q3 		$309 Buy
12
+10
+500% +$261 ﹤0.01% 7347
2024
Q2 		$45 Buy
2
+1
+100% +$38 ﹤0.01% 7527
2024
Q1 		$20 Hold
1
– – ﹤0.01% 7720
2023
Q4 		$34 Hold
1
– – ﹤0.01% 7723
2023
Q3 		$58 Hold
1
– – ﹤0.01% 7479
2023
Q2 		$111 Hold
1
– – ﹤0.01% 7488
2023
Q1 		$187 Hold
1
– – ﹤0.01% 7521
2022
Q4 		$124 Sell
1
-1
-50% -$175 ﹤0.01% 7681
2022
Q3 		$0 Buy
2
+1
+100% +$451 ﹤0.01% 7678
2022
Q2 		$1K Hold
1
– – ﹤0.01% 7651
2022
Q1 		$1K Hold
1
– – ﹤0.01% 7817
2021
Q4 		$1K Sell
1
-63
-98% -$124K ﹤0.01% 7841
2021
Q3 		$173K Buy
64
+63
+6,300% +$132K ﹤0.01% 6076
2021
Q2 		$1K Sell
1
-7
-88% -$10.6K ﹤0.01% 7581
2021
Q1 		$13K Buy
8
+7
+700% +$10.6K ﹤0.01% 6861
2020
Q4 		$1K Hold
1
– – ﹤0.01% 6929
2020
Q3 		$1K Hold
1
– – ﹤0.01% 6636
2020
Q2 		$1K Hold
1
– – ﹤0.01% 6507
2020
Q1 		$1K Hold
1
– – ﹤0.01% 6443
2019
Q4 		$1K Hold
1
– – ﹤0.01% 6548
2019
Q3 		$1K Hold
1
– – ﹤0.01% 6527
2019
Q2 		$1K Hold
1
– – ﹤0.01% 6511
2019
Q1 		$2K Hold
1
– – ﹤0.01% 6439
2018
Q4 		$3K Hold
1
– – ﹤0.01% 6365
2018
Q3 		$1K Buy
+1
New +$2.08K ﹤0.01% 6607

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley's ADIL Position: Q1 2026 in Review

Morgan Stanley opened a new position in Adial Pharmaceuticals (ADIL) in Q1 2026: 50 shares worth $90. The stake represents ﹤0.01% of the portfolio and ranks #7816 among its holdings. This is a return to the name: Morgan Stanley previously reported a position in ADIL as recently as Q3 2024.

Morgan Stanley first reported a position in ADIL in Q3 2018 and has held it in 26 quarters since. The position peaked at $173K in Q3 2021. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Morgan Stanley held 50 shares of Adial Pharmaceuticals worth $90 as of Q1 2026.
  • Adial Pharmaceuticals was a new Morgan Stanley position in Q1 2026.
  • Adial Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7816 holding.
  • Morgan Stanley first reported a position in Adial Pharmaceuticals in Q3 2018 and has held it in 26 quarters since.
  • Morgan Stanley's Adial Pharmaceuticals position peaked at $173K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.